Navigation Links
New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development
Date:6/18/2009

to find better tools and novel approaches to implement the requirements of regulations efficiently and cost effectively," says Dr. Suzanne Gagnon, Chief Medical Officer, ICON Clinical Research.

The report was commissioned by ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and developed by IMS Health, the world's leading provider of market intelligence to the pharmaceutical and healthcare industries.

Phase IV activities, including observational trials or "safety registries" that gather data on the use and effectiveness of medications in the real world are expected to be particularly impacted by new regulations, according to the survey. Eighty percent of respondents anticipate the number of Phase IV trials to grow over the next five years, while 58 percent indicated that safety registries increasingly will be used to monitor drug safety at every stage of the clinical trial process.

"The move toward greater transparency around drug safety remains a regulatory and political priority worldwide," says Nigel Burrows, Senior Principal, Management Consulting, IMS. "The pharmaceutical industry has and continues to respond to this challenge, both in drug clinical development and commercialisation. These efforts have the potential to go beyond simply satisfying regulatory requirements, leading to more clinically effective and commercially viable advances that improve outcomes and set new standards of care."

Notes to editors

Survey methodology

ICON commissioned IMS Health to conduct a survey that explored global trends in drug safety issues, and to evaluate the impact of recent safety regulations on the industry. A total of 140 people were questioned via a telephone interview, and included the heads of pharmacovigilance, safety and clinical research functions among pharmaceutical and biotechn
'/>"/>

SOURCE ICON plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
2. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
3. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
4. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
5. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
6. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
7. New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
8. Results From Study Show Promising Efficacy and Safety Results for Cortheras Relaxin in Acute Heart Failure
9. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
10. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
11. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 According to a new ... Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology ... & Geography - Global Forecast to 2020", published by ... around 17,689.0 Million USD by 2020 at a CAGR ... 2020. Browse 191 Tables and 38 ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Originally discovered by Welfide (Mitsubishi Tanabe ... Ltd) as an inflammatory drug, pranoprofen was later ... Ltd under the trade name of pranopulin for ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Developed by Roche under the trade name ... in the world. In Feb.26, 2010, it was approved ... injections available in China all ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Bevacizumab Market 2015-2019 2
... from Serial Outpatient Infusion Study in Patients with,Chronic ... Cardiology 56th Annual Scientific Session --, MOUNTAIN VIEW, ... Scios Inc. announced today that an exploratory,920-patient, Phase ... on the primary endpoint, a composite of death ...
... March 25, 2007 /PRNewswire/ -- Once-daily,dosing with ... antagonist, was associated with improvements,in signs and ... hospitalized patients receiving conventional care, without an,adverse ... These,data are from the short- and long-term ...
Cached Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
(Date:8/28/2015)... ... 2015 , ... The Nashville Business Journal recently announced its ... Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one of ... Awards will recognize Nashville military veterans who, through their professional and personal efforts, ...
(Date:8/28/2015)... Arizona (PRWEB) , ... August 28, 2015 , ... ... and increased patient loyalty at a low cost. Personalized with practice contact information ... and existing patients. Dental offices can also incorporate Calendars into seasonal mailings, thank ...
(Date:8/28/2015)... ... ... Mendon, IL, home of the Adams County Fairgrounds, was treated once again ... cause. In its second year, the “Music With A Mission” benefit concert was held ... of “Music With A Mission” is to raise money to help fund music education ...
(Date:8/28/2015)... ... 2015 , ... The Louis W. Sullivan Institute for ... transform quality and efficiency of healthcare delivery worldwide, announced the release of a ... being publicly shared to document progress and inform policy in a report issued ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit Advisors ... TJS Insurance Group as its newest Partner Firm. Founded in 1924 and headquartered ... them focused on their goals. Within the past 10 years, TJS Insurance Group ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3
... 21 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... in conjunction with the American College of,Rheumatology Meeting ... Members of Rigel,s senior management team will provide ... a novel, oral Syk kinase,inhibitor. R788 is currently ...
... the,availability of MarketStats for health care technology equities ... a perspective on the,aforementioned equities and the opportunity ... Investors can view MarketStats by visiting: ... social networking site for,investors., Today,s MarketStats for ...
... Aid, an application for iPhone and iPod Touch, is released today ... the steps of Cardiopulmonary Resuscitation or how to act when someone ... ... 2008 -- Phone Aid, an application for iPhone and iPod Touch, ...
... has expanded the reach of its custom commercial printing by ... Canada and Europe. , ... Ft. ... commercial printing customers with international shipping options via FedEx, UPS ...
... Unchanged, ST. LOUIS, Oct. 20 KV Pharmaceutical ... Hologic, Inc., the,holder of the New Drug Application (NDA) ... has extended the PDUFA date on,Gestiva(TM) for ninety days ... extension is in line with the FDA,s standard operating ...
... heart attacks , , MONDAY, Oct. 20 (HealthDay News) -- A ... reduce the risks of surgery. , The death rate for ... higher in the 30 days after an operation than for ... according to a report in the October issue of the ...
Cached Medicine News:Health News:Rigel to Webcast Investor Update on October 27, 2008 2Health News:SectorWatch.biz Issues MarketStats on NWCI, ERES, STJ, MDT, BSX, and CSCX 2Health News:Save Lives with Your Mobile Phone - Doctor Releases First Aid Application for iPhone 2Health News:My1Stop.com Takes Commercial Printing Global with International Shipping of Custom Printed Products 2Health News:KV Provides Update on Gestiva(TM) PDUFA Date 2Health News:KV Provides Update on Gestiva(TM) PDUFA Date 3Health News:KV Provides Update on Gestiva(TM) PDUFA Date 4Health News:Questions Continue About Using Beta Blockers Before Surgery 2Health News:Questions Continue About Using Beta Blockers Before Surgery 3
Resorbable fixation system 1.5/2.0....
... By combining intra-operative ... imagery, Medtronic Surgical Navigation ... revolutionary product called SonoNav ... system built on the ...
... the two steps are performed in sequence ... single use disposable cartridge and placed in ... touches a button, and the cycle begins. ... Then the integral syringe pump concentrates fibrinogen, ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical...
Medicine Products: